Capital International Investors
RAPP

Capital International Investors’s Rapport Therapeutics RAPP Stock Holding History

Capital International Investors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96.9M Sell
3,097,973
-304,556
-9% -$8.57M 0.02% 287
2025
Q4 		$103M Hold
3,402,529
– – 0.02% 293
2025
Q3 		$101M Buy
3,402,529
+800,000
+31% +$14.3M 0.02% 295
2025
Q2 		$29.6M Hold
2,602,529
– – 0.01% 373
2025
Q1 		$26.1M Hold
2,602,529
– – 0.01% 376
2024
Q4 		$46.2M Hold
2,602,529
– – 0.01% 346
2024
Q3 		$53.3M Sell
2,602,529
-2
-0% -$43 0.01% 319
2024
Q2 		$60.5M Buy
+2,602,531
New +$60.3M 0.01% 299

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital International Investors's RAPP Position: Q1 2026 in Review

Capital International Investors reduced its Rapport Therapeutics (RAPP) stake by 9% in Q1 2026, selling an estimated $8.57M and leaving 3,097,973 shares worth $96.9M. The position accounts for 0.02% of the portfolio, ranked #287.

Capital International Investors first reported a position in RAPP in Q2 2024 and has held it in 8 quarters since. The position peaked at $103M in Q4 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Capital International Investors held 3,097,973 shares of Rapport Therapeutics worth $96.9M as of Q1 2026.
  • Capital International Investors sold 304,556 Rapport Therapeutics shares in Q1 2026, an estimated $8.57M.
  • Rapport Therapeutics made up 0.02% of Capital International Investors's portfolio in Q1 2026, its #287 holding.
  • Capital International Investors first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Capital International Investors's Rapport Therapeutics position peaked at $103M in Q4 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Capital International Investors's 13F filing for Q1 2026, filed 13 May 2026.